Janko Pasternak J, Nebojsa Budakov B, Andrej Petres V
Department of Vascular Surgery, Clinical Centre of Vojvodina, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia.
Department of Radiology, Clinical Centre of Vojvodina, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia.
Arch Iran Med. 2018 Mar 1;21(3):118-121.
Peripheral arterial occlusive disease (PAD) includes acute and chronic disorders of the blood supply as a result of obstruction of blood flow in the arteries of the limb. Treatment of PAD can be conservative, surgical and endovascular. Percutaneous transluminal angioplasty with or without stenting has become a recognized method, which is increasingly used in treatment of arterial occlusive disease. This study aimed to determine early results of endovascular treatment of critical limb ischemia (CLI) patients with infrapopliteal lesions.
The study included 69 patients (46 men; mean age 65 years, range 38-84) with CLI (class 4 to 6 according to Rutherford). The primary study endpoints were absence of major amputation of the target limb at 6 months and occurance of local and systemic complications specifically related to use of endovascular treatment.
Major amputation was avoided in 61 patients. Through 6 months, 6 patients underwent additional revascularization. One local complication (clinicaly significant dissection of popliteal artery) occurred, and it was resolved by stent implantation. There were no cases of systemic complications and death during the follow-up period. Rates of major amputation were 12.3% for diabetics versus 8.3% for non-diabetics.
Our data showed that endovascular treatment of infrapopliteal disease is an effective and safe treatment in patients experiencing CLI, provides high limb preservation and low complication rates. Study outcomes support endovascular treatment as a primary option for patients experiencing CLI due to below the knee (BTK) occlusive disease.
外周动脉闭塞性疾病(PAD)包括由于肢体动脉血流阻塞导致的急性和慢性血液供应障碍。PAD的治疗方法包括保守治疗、手术治疗和血管内治疗。经皮腔内血管成形术(无论是否置入支架)已成为一种公认的方法,越来越多地用于治疗动脉闭塞性疾病。本研究旨在确定血管内治疗下肢严重缺血(CLI)合并腘动脉以下病变患者的早期疗效。
本研究纳入69例CLI患者(根据卢瑟福分级为4至6级)(46例男性;平均年龄65岁,范围38 - 84岁)。主要研究终点为6个月时目标肢体未进行大截肢以及与血管内治疗相关的局部和全身并发症的发生情况。
61例患者避免了大截肢。在6个月期间,6例患者接受了额外的血运重建。发生了1例局部并发症(腘动脉临床显著夹层),通过植入支架得以解决。随访期间无全身并发症和死亡病例。糖尿病患者的大截肢率为12.3%,非糖尿病患者为8.3%。
我们的数据表明,血管内治疗腘动脉以下疾病对于CLI患者是一种有效且安全的治疗方法,具有高肢体保留率和低并发症发生率。研究结果支持血管内治疗作为因膝下(BTK)闭塞性疾病导致CLI患者的首选治疗方案。